Achieving High CAR T Cell Transduction Using The Automated End-To-End Sefia™ Cell Therapy Platform

Hematologic malignancies remain a growing global burden, and while autologous CAR T therapies show strong clinical promise, manufacturing complexity continues to limit patient access. Advances in automation are helping address this gap by reducing operator dependency, improving consistency, and lowering production costs—but many current platforms still lack the flexibility needed for evolving workflows. A modular, functionally closed approach enables scalable CAR T expansion alongside higher throughput, while integration with digital automation and electronic batch records supports streamlined execution and real-time monitoring. Evidence from GMP-aligned runs with healthy donors highlights how controlled automation can maintain key functional attributes, including cytotoxicity, phenotype, and cytokine production.

See how these innovations are shaping more efficient, reproducible CAR T manufacturing strategies.